Analysts’ Recommendations for UnitedHealth Group
Analysts’ recommendations for UnitedHealth Group
UnitedHealth Group is the world’s largest healthcare company in terms of revenue. In fiscal 2017, it generated revenue of $201 billion. Set to release its 1Q18 results on April 17, 2018, the company has undergone recent management changes. In November 2017, it established the Optum Ventures investment fund. To learn more, read UnitedHealth Group’s Management Changes and Key Developments.
The company is focused on establishing itself as an integrated health services company and has undertaken a number of strategic acquisitions recently. In this article, we’ll look at analysts’ recommendations and target prices for UNH ahead of the company’s 1Q18 earnings release.
Interested in UNH? Don't miss the next report.
Receive e-mail alerts for new research on UNH
According to Reuters, of the 23 analysts covering UNH on April 12, 2018, 11 recommended “strong buy” and 12 recommended “buy.” There were no “hold” or “sell” recommendations.
As of April 12, analysts’ 12-month target price for UnitedHealth Group stock was $270.70, implying a ~21% return based on its closing price of $221.90 on April 11. Analysts’ 12-month target prices for peers Anthem (ANTM), CVS Health (CVS), and Aetna (AET) were $278.47, $88.43, and $206.24, respectively, representing potential returns of approximately 26%, 37.6%, and 18.7%.
Recommendation revisions and updates
On March 8, 2018, Barclays initiated coverage on UNH stock with an “overweight” rating and has given it a target price of $265. On January 17, 2018, a number of brokerages, including Oppenheimer, Deutsche Bank, Leerink, and Credit Suisse, raised their target prices for UNH after the company raised its 2018 outlook with its 4Q17 earnings release on January 16, 2018.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!